Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | -5.52% | -16.99% | -53.41% |
Jun. 04 | Inotiv, Inc. Enters into A Fifth Amendment to the Credit Agreement | CI |
Jun. 03 | Inotiv to Pay $35 Million for Canine-Breeding Facility Violations | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-53.41% | 47.01M | D+ | ||
+55.55% | 59.34B | B- | ||
+43.17% | 40.24B | A | ||
-4.71% | 39.88B | B | ||
-5.56% | 28.55B | C | ||
+13.76% | 27.26B | B- | ||
-22.00% | 19.23B | B | ||
+31.50% | 12.61B | C+ | ||
+2.16% | 12.49B | B+ | ||
+25.70% | 12.28B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NOTV Stock
- Ratings Inotiv, Inc.